Will You Benefit from the CMS GLP-1 Bridge Program?

Starting July 1st the Medicare GLP-1 Bridge program rolled out bringing GLP-1 meds (Foundayo®, Wegovy®, Zepbound® KwikPen®) to Medicare beneficiaries for a $50 copay for the specific medical purpose of weight loss. (Until the Bridge Program, Medicare did not cover drugs for the sole purpose of weight loss.) This program is administered by Medicare and is separate and apart from any Medicare drug plan in which you may be enrolled. Your doctor must submit you to the program for prior authorization and there are clinical guidelines for who can qualify. See the official information page at link below and consult with your doctor to pursue participation in the program if interested.

Five Things to be Aware of

1. The $50 copay for your GLP-1 medication does not count towards your Part D annual maximum out-of-pocket cap of $2,100 (for 2026). Because the GLP-1 Bridge Program operates outside of your Part D benefit, the $50 that you pay each month for your weight loss drug does not accrue towards that Part D cap.

2. This is a temporary program, not permanent. The bridge program runs from July 1st, 2026, through December 31st, 2027; a year and a half. After that, what happens depends on the Balance Model that CMS is launching in the future. That date is still undecided. Under the Balance Model, coverage of GLP-1 drugs for weight loss will move inside of the Part D benefit, which means individual Part D plans will need to decide whether to participate. Some will, some will not, depending on if carriers can find the funding to support it.

3. Your plan choice during the annual election period in the fall of 2027 is critical. It's critical every year, but especially next year if you want to be in a plan that participates in the Balance Model. As of this writing, CMS has not released a list of participating plans.

4. If you already use one of the GLP-1 drugs covered in the Bridge Program for a covered Part D condition, you can't arbitrarily decide to get that GLP-1 drug through the Bridge Program instead just to get a lower copay. Let's say that you currently take Wegovy through your Part D plan because your doctor prescribed it to reduce cardiovascular risk, which is a use that Part D covers. You cannot also get Wegovy through the Bridge Program for weight loss. If your medication is prescribed for a use that's already coverable under Part D, then the provider needs to go through your Part D plan, not the Bridge Program.

5. Prior authorization is required and your doctor drives that process. Your medical provider must submit a prior authorization request that confirms that you meet the clinical criteria. That includes confirming your BMI, your qualifying conditions, and that you've been prescribed the drug in combination with ongoing lifestyle modifications, including structured nutrition and physical activity consistent with the FDA approved label of these drugs. In other words, the Bridge Program does not just rubber stamp anyone who wants to give GLP-1 meds a try.

References

CMS Official Information Page: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

Barley Medical (a medical billing service) has some plain-language interpretation of the clinical details here: https://barleymedical.com/denials/glp1-weight-loss-coverage/